European Biotechnology Network had the good fortune to moderate the 8th Berlin Conference on IP in Life Science, which this year had a focus on natural products. That will be interesting, I thought to myself, thinking about the world of complex structures and challenging development pathways. Interesting soon paled into insignificance as I fell headlong into the tiger trap that is the Nagoya Protocol, coming soon folks to a country near you.
SuperScript® III Reverse Transcriptase
ProductsSuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs.
High-Precision Weighing
ProductsMETTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications.
3PBiopharmaceuticals offers experience in CELL FREE technology
ProductsThe experience acquired with one of its clients allows 3P the capability to offer this alternative technology in its services pipeline.
BioShake Series
ProductsThe BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications.
BD Peptone Starter Paks
ProductsWith 100g samples, the Peptone Starter Paks allow for you to identify the correct supplements for your specific cell line faster.
Nagoya protecting resources with paperwork
OpinionEuropean Biotechnology Network had the good fortune to moderate the 8th Berlin Conference on IP in Life Science, which this year had a focus on natural products. That will be interesting, I thought to myself, thinking about the world of complex structures and challenging development pathways. Interesting soon paled into insignificance as I fell headlong into the tiger trap that is the Nagoya Protocol, coming soon folks to a country near you.
Expert opinion: Don’t cross the Rubicon
OpinionModern biotechnology has already helped many patients and we need to continue research and development because many diseases cannot be cured yet. However, inappropriate use of technology has serious side effects for patients and society. That is why strict rules if possible at cross-national level are necessary.
Don’t misinterpret the results of the referendum
OpinionDuring the Swiss Biotech Day in Zurich, the Swiss Biotech Report 2014 highlighted the most important innovation drivers in the country’s industry and summarised the sector’s most relevant topics.
Europe triumphs at kicking the GM ball into the long grass
OpinionYou would have to be blind, deaf and living in a hole for the last twenty years to not know that Europe struggles with the whole GMO thing.
Growing potential for cancer immunotherapy
OpinionImmune therapies have rapidly gained the attention of the medical community as a new hope for cancer treatment. Arguably, the intersection of immunology and oncology represents one of the most promising approaches, which may have a significant impact for patients with cancer today.